S&P 500   5,053.38 (-0.17%)
DOW   37,808.60 (+0.19%)
QQQ   430.55 (-0.12%)
AAPL   169.14 (-2.06%)
MSFT   416.88 (+0.78%)
META   501.90 (+0.33%)
GOOGL   154.95 (+0.06%)
AMZN   183.94 (+0.17%)
TSLA   156.66 (-2.98%)
NVDA   875.51 (+1.80%)
AMD   163.68 (+2.10%)
NIO   3.83 (-1.54%)
BABA   70.04 (-0.82%)
T   16.03 (-1.29%)
F   12.17 (-0.49%)
MU   121.28 (-0.07%)
GE   156.07 (+1.54%)
CGC   6.81 (-2.44%)
DIS   114.05 (+0.97%)
AMC   2.82 (+14.17%)
PFE   25.82 (-0.35%)
PYPL   63.92 (+0.65%)
XOM   118.48 (-1.00%)
S&P 500   5,053.38 (-0.17%)
DOW   37,808.60 (+0.19%)
QQQ   430.55 (-0.12%)
AAPL   169.14 (-2.06%)
MSFT   416.88 (+0.78%)
META   501.90 (+0.33%)
GOOGL   154.95 (+0.06%)
AMZN   183.94 (+0.17%)
TSLA   156.66 (-2.98%)
NVDA   875.51 (+1.80%)
AMD   163.68 (+2.10%)
NIO   3.83 (-1.54%)
BABA   70.04 (-0.82%)
T   16.03 (-1.29%)
F   12.17 (-0.49%)
MU   121.28 (-0.07%)
GE   156.07 (+1.54%)
CGC   6.81 (-2.44%)
DIS   114.05 (+0.97%)
AMC   2.82 (+14.17%)
PFE   25.82 (-0.35%)
PYPL   63.92 (+0.65%)
XOM   118.48 (-1.00%)
S&P 500   5,053.38 (-0.17%)
DOW   37,808.60 (+0.19%)
QQQ   430.55 (-0.12%)
AAPL   169.14 (-2.06%)
MSFT   416.88 (+0.78%)
META   501.90 (+0.33%)
GOOGL   154.95 (+0.06%)
AMZN   183.94 (+0.17%)
TSLA   156.66 (-2.98%)
NVDA   875.51 (+1.80%)
AMD   163.68 (+2.10%)
NIO   3.83 (-1.54%)
BABA   70.04 (-0.82%)
T   16.03 (-1.29%)
F   12.17 (-0.49%)
MU   121.28 (-0.07%)
GE   156.07 (+1.54%)
CGC   6.81 (-2.44%)
DIS   114.05 (+0.97%)
AMC   2.82 (+14.17%)
PFE   25.82 (-0.35%)
PYPL   63.92 (+0.65%)
XOM   118.48 (-1.00%)
S&P 500   5,053.38 (-0.17%)
DOW   37,808.60 (+0.19%)
QQQ   430.55 (-0.12%)
AAPL   169.14 (-2.06%)
MSFT   416.88 (+0.78%)
META   501.90 (+0.33%)
GOOGL   154.95 (+0.06%)
AMZN   183.94 (+0.17%)
TSLA   156.66 (-2.98%)
NVDA   875.51 (+1.80%)
AMD   163.68 (+2.10%)
NIO   3.83 (-1.54%)
BABA   70.04 (-0.82%)
T   16.03 (-1.29%)
F   12.17 (-0.49%)
MU   121.28 (-0.07%)
GE   156.07 (+1.54%)
CGC   6.81 (-2.44%)
DIS   114.05 (+0.97%)
AMC   2.82 (+14.17%)
PFE   25.82 (-0.35%)
PYPL   63.92 (+0.65%)
XOM   118.48 (-1.00%)
NASDAQ:AMRX

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

$5.47
-0.07 (-1.26%)
(As of 01:46 PM ET)
Today's Range
$5.38
$5.54
50-Day Range
$5.31
$6.34
52-Week Range
$1.40
$6.46
Volume
763,324 shs
Average Volume
1.51 million shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.31

Amneal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.7% Upside
$7.31 Price Target
Short Interest
Healthy
2.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Amneal Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
12.00%
From $0.50 to $0.56 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.67 out of 5 stars

Medical Sector

456th out of 930 stocks

Pharmaceutical Preparations Industry

210th out of 429 stocks

AMRX stock logo

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Stock Price History

AMRX Stock News Headlines

Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Top 3 Pharma Innovators to Watch Closely
Amneal Pharmaceuticals (AMRX) Gets a Buy from Barclays
Amneal Pharmaceuticals: Q4 Earnings Insights
Amneal Pharmaceuticals Up 20% In Pre-market - Update
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2024
Today
4/16/2024
Next Earnings (Confirmed)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMRX
Previous Symbol
NASDAQ:AMRX
Employees
7,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.31
High Stock Price Target
$8.00
Low Stock Price Target
$6.25
Potential Upside/Downside
+34.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-83,990,000.00
Pretax Margin
-1.68%

Debt

Sales & Book Value

Annual Sales
$2.39 billion
Cash Flow
$1.33 per share
Book Value
$0.07 per share

Miscellaneous

Free Float
253,404,000
Market Cap
$1.67 billion
Optionable
Optionable
Beta
1.33
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives


AMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price target for 2024?

4 brokerages have issued 1-year target prices for Amneal Pharmaceuticals' shares. Their AMRX share price targets range from $6.25 to $8.00. On average, they predict the company's share price to reach $7.31 in the next year. This suggests a possible upside of 32.7% from the stock's current price.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2024?

Amneal Pharmaceuticals' stock was trading at $6.07 at the start of the year. Since then, AMRX shares have decreased by 9.2% and is now trading at $5.51.
View the best growth stocks for 2024 here
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,400,000 shares, an increase of 15.9% from the March 15th total of 2,070,000 shares. Based on an average trading volume of 1,530,000 shares, the short-interest ratio is presently 1.6 days. Currently, 2.2% of the company's stock are sold short.
View Amneal Pharmaceuticals' Short Interest
.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our AMRX earnings forecast
.

How can I listen to Amneal Pharmaceuticals' earnings call?

Amneal Pharmaceuticals will be holding an earnings conference call on Friday, May 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) issued its earnings results on Friday, March, 1st. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.07. The firm earned $616.98 million during the quarter, compared to the consensus estimate of $630.67 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 126.04% and a negative net margin of 3.51%.

What ETFs hold Amneal Pharmaceuticals' stock?

ETFs with the largest weight of Amneal Pharmaceuticals (NASDAQ:AMRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).Invesco Russell 2000 Dynamic Multifactor ETF (OMFS).

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY 2024 earnings guidance on Friday, March, 1st. The company provided earnings per share (EPS) guidance of 0.530-0.630 for the period, compared to the consensus EPS estimate of 0.600. The company issued revenue guidance of $2.6 billion-$2.7 billion, compared to the consensus revenue estimate of $2.6 billion.

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.08%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMRX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners